Janssen PCI-32765FLR3001 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)

Cancer - Lymphoma

Diagnosis of B-cell indolent Non-Hodgkin lymphoma with subtype limited to follicular lymphoma or marginal zone lymphoma; at least 1 prior treatment with a CD20 antibody combination chemotherapy regimen; disease that has relapsed or was refractory after prior chemotherapy.

Tiffany Pearce